← SynDRA
NAZARTINIB
SynDRA canonical compound SYN0038550 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- Epidermal growth factor receptor inhibitor
Drug classes
Cross-references
Synonyms
- EGF816
- EGF-816
- NVP-EGF816-NX
- EGF 816
- KE7K32EME8
- nazartinibum
- RefChem:832112
- Nazartinib [USAN]
- Nazartinib(EGF816)
- C26H31ClN6O2
- UNII-KE7K32EME8
- MFCD28963918
- Nazartinib (EGF816)
- NAZARTINIB [INN]
- Nazartinib (USAN/INN)
- NAZARTINIB [WHO-DD]
- GTPL9204
- orb1304136
- SCHEMBL16767232
- SCHEMBL29355708
- SCHEMBL29470539
- GLXC-90490
- EX-A1640
- BDBM50160870
- NSC787027
- s7824
- Nazartinib (EGF816, NVS-816)
- AKOS030632782
- CCG-269658
- EBC-221045
- NSC-787027
- compound 47 [PMID: 27433829]
- AC-29881
- AS-75243
- HY-12872
- C72867
- D11430
- F865697
- BRD-K22514639-001-04-0
Look up NAZARTINIB in the interactive SynDRA portal →